Methods and compositions for treating hypoglycemic disorders

Patent metadata

Field	Value
Publication number	US-10188702-B2
Application number	US-201715453823-A
Country	US
Kind code	B2
Filing date	Mar 8, 2017
Priority date	Jan 8, 2007
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.

First claim

What is claimed is:

1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism comprising administering to the subject an effective amount of a peptide wherein the amino acid sequence of the peptide consists of the amino acid sequence set forth in SEQ ID NO: 1.

2. The method of claim 1 , wherein the congenital hyperinsulinism is associated with a genetic abnormality or a mutation.

3. The method of claim 2 , wherein the genetic abnormality or the mutation is associated with a gene selected from the group consisting of a gene encoding glucokinase (GCK), a gene encoding glutamate dehydrogenase (GLUD-1), and a gene encoding mitochondrial enzyme short-chain 3-hydroxyacyl-CoA dehydrogenase (HADHSC).

4. The method of claim 1 , wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof.

5. The method of claim 4 , wherein the peptide is administered subcutaneously.

6. The method of claim 4 , wherein the peptide is administered intravenously.

7. The method of claim 1 , wherein the peptide is administered by infusion.

Assignees

• Univ Pennsylvania
• Childrens Hospital Of Philadelphia

Inventors

• Stoffers Doris
• De Leon Diva D
• Stanley Charles

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K38/26 Primary

  Glucagons · CPC title